FDA to Biosimilar Sponsors: Know Your (Analytical) Limits

Drug Industry Daily
Science has advanced enough that biosimilar sponsors can make a strong case for their product’s similarities to a reference product, but it’s going to be “critical” that sponsors understand the limits of their analytics, the FDA says in a new draft guidance document issued Tuesday.

To View This Article:


Subscribe To Drug Industry Daily